Search
for

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community EMA is re-examining Winlevi (clascoterone at lower concentration)

      in Treatment  9 upvotes 9 months ago
      Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

      community Fevipiprant 2019!

       15 upvotes 9 years ago
      The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

      community Allergan recruiting for Setipiprant trial in the US

       12 upvotes 8 years ago
      The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.